Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 143

1.

CD8⁺ Foxp3⁺ tumor infiltrating lymphocytes accumulate in the context of an effective anti-tumor response.

Le DT, Ladle BH, Lee T, Weiss V, Yao X, Leubner A, Armstrong TD, Jaffee EM.

Int J Cancer. 2011 Aug 1;129(3):636-47. doi: 10.1002/ijc.25693. Epub 2010 Nov 12.

PMID:
20857491
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

OX40 costimulation synergizes with GM-CSF whole-cell vaccination to overcome established CD8+ T cell tolerance to an endogenous tumor antigen.

Murata S, Ladle BH, Kim PS, Lutz ER, Wolpoe ME, Ivie SE, Smith HM, Armstrong TD, Emens LA, Jaffee EM, Reilly RT.

J Immunol. 2006 Jan 15;176(2):974-83.

PMID:
16393983
[PubMed - indexed for MEDLINE]
Free Article
4.

Reversing tumor immune suppression with intratumoral IL-12: activation of tumor-associated T effector/memory cells, induction of T suppressor apoptosis, and infiltration of CD8+ T effectors.

Kilinc MO, Aulakh KS, Nair RE, Jones SA, Alard P, Kosiewicz MM, Egilmez NK.

J Immunol. 2006 Nov 15;177(10):6962-73.

PMID:
17082611
[PubMed - indexed for MEDLINE]
Free Article
5.
6.

Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice.

Machiels JP, Reilly RT, Emens LA, Ercolini AM, Lei RY, Weintraub D, Okoye FI, Jaffee EM.

Cancer Res. 2001 May 1;61(9):3689-97.

PMID:
11325840
[PubMed - indexed for MEDLINE]
Free Article
7.
8.

Nondominant CD8 T cells are active players in the vaccine-induced antitumor immune response.

Uram JN, Black CM, Flynn E, Huang L, Armstrong TD, Jaffee EM.

J Immunol. 2011 Apr 1;186(7):3847-57. doi: 10.4049/jimmunol.1000361. Epub 2011 Feb 23.

PMID:
21346233
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Peptide vaccination breaks tolerance to HER-2/neu by generating vaccine-specific FasL(+) CD4(+) T cells: first evidence for intratumor apoptotic regulatory T cells.

Gritzapis AD, Voutsas IF, Lekka E, Papamichail M, Baxevanis CN.

Cancer Res. 2010 Apr 1;70(7):2686-96. doi: 10.1158/0008-5472.CAN-09-2517. Epub 2010 Mar 16.

PMID:
20233867
[PubMed - indexed for MEDLINE]
Free Article
10.

Increased tumor-infiltrating CD8(+)Foxp3(+) T lymphocytes are associated with tumor progression in human gastric cancer.

Peng LS, Zhuang Y, Shi Y, Zhao YL, Wang TT, Chen N, Cheng P, Liu T, Liu XF, Zhang JY, Zuo QF, Mao XH, Guo G, Lu DS, Yu PW, Zou QM.

Cancer Immunol Immunother. 2012 Nov;61(11):2183-92. doi: 10.1007/s00262-012-1277-6. Epub 2012 May 22.

PMID:
22729557
[PubMed - indexed for MEDLINE]
11.
12.

Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response.

Ercolini AM, Ladle BH, Manning EA, Pfannenstiel LW, Armstrong TD, Machiels JP, Bieler JG, Emens LA, Reilly RT, Jaffee EM.

J Exp Med. 2005 May 16;201(10):1591-602. Epub 2005 May 9.

PMID:
15883172
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

In the FVB/N HER-2/neu transgenic mouse both peripheral and central tolerance limit the immune response targeting HER-2/neu induced by Listeria monocytogenes-based vaccines.

Singh R, Paterson Y.

Cancer Immunol Immunother. 2007 Jun;56(6):927-38. Epub 2006 Nov 28.

PMID:
17131121
[PubMed - indexed for MEDLINE]
14.

The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors.

Reilly RT, Machiels JP, Emens LA, Ercolini AM, Okoye FI, Lei RY, Weintraub D, Jaffee EM.

Cancer Res. 2001 Feb 1;61(3):880-3.

PMID:
11221874
[PubMed - indexed for MEDLINE]
Free Article
15.

HSP110-HER2/neu chaperone complex vaccine induces protective immunity against spontaneous mammary tumors in HER-2/neu transgenic mice.

Manjili MH, Wang XY, Chen X, Martin T, Repasky EA, Henderson R, Subjeck JR.

J Immunol. 2003 Oct 15;171(8):4054-61.

PMID:
14530326
[PubMed - indexed for MEDLINE]
Free Article
16.

Antibody association with HER-2/neu-targeted vaccine enhances CD8 T cell responses in mice through Fc-mediated activation of DCs.

Kim PS, Armstrong TD, Song H, Wolpoe ME, Weiss V, Manning EA, Huang LQ, Murata S, Sgouros G, Emens LA, Reilly RT, Jaffee EM.

J Clin Invest. 2008 May;118(5):1700-11. doi: 10.1172/JCI34333.

PMID:
18398507
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

TCR transgenic CD8+ T cells activated in the presence of TGFbeta express FoxP3 and mediate linked suppression of primary immune responses and cardiac allograft rejection.

Kapp JA, Honjo K, Kapp LM, Xu Xy, Cozier A, Bucy RP.

Int Immunol. 2006 Nov;18(11):1549-62. Epub 2006 Sep 11.

PMID:
16966495
[PubMed - indexed for MEDLINE]
Free Article
18.

Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.

Duraiswamy J, Kaluza KM, Freeman GJ, Coukos G.

Cancer Res. 2013 Jun 15;73(12):3591-603. doi: 10.1158/0008-5472.CAN-12-4100. Epub 2013 Apr 30.

PMID:
23633484
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Tumor-reactive CD8+ early effector T cells identified at tumor site in primary and metastatic melanoma.

Anichini A, Molla A, Vegetti C, Bersani I, Zappasodi R, Arienti F, Ravagnani F, Maurichi A, Patuzzo R, Santinami M, Pircher H, Di Nicola M, Mortarini R.

Cancer Res. 2010 Nov 1;70(21):8378-87. doi: 10.1158/0008-5472.CAN-10-2028. Epub 2010 Sep 21.

PMID:
20861189
[PubMed - indexed for MEDLINE]
Free Article
20.

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk